Xolair Treatment for Milk Allergic Children - Full Text View

Sponsor:	Children's Hospital Boston
Collaborator:	Stanford University
Information provided by:	Children's Hospital Boston
ClinicalTrials.gov Identifier:	NCT00968110

Purpose

This is a pilot feasibility study, using Xolair pretreatment for oral milk desensitization. The major assessment will be safety, and the investigators will evaluate for any type of reaction, including allergic reactions that occur during the course of the study.

Condition	Intervention	Phase
Milk Allergy	Drug: omalizumab	Phase 0

Children's Hospital Boston has indicated that access to an investigational treatment associated with this study is available outside the clinical trial.

Study Type:	Interventional
Study Design:	Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	Xolair (Omalizumab) Enhances Oral Tolerance Induction in Milk Allergic Children

Resource links provided by NLM:

MedlinePlus related topics: Allergy

Drug Information available for: Omalizumab

U.S. FDA Resources

Further study details as provided by Children's Hospital Boston:

Primary Outcome Measures:

The major goal of this study is to assess the safety of Xolair in young children, and the safety of oral desensitization in patients pretreated with Xolair [ Time Frame: week 53 ] [ Designated as safety issue: Yes ]

Enrollment:	10
Study Start Date:	March 2009
Estimated Study Completion Date:	July 2011
Estimated Primary Completion Date:	April 2011 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: Xolair All patients will receive Xolair treatment for 16 weeks.	Drug: omalizumab Dosing table established for omalizumab Other Name: Xolair

Detailed Description:

Our hypothesis is that pretreatment with anti-IgE mAb will greatly reduce the side effects and allergic reactions that occur during oral desensitization to foods and will enhance the development of oral tolerance in patients with severe milk allergy. Once desensitized to milk, children will be able to tolerate milk in a Double Blind Placebo Controlled Food Challenge.

The study will also evaluate whether Xolair provides a robust durability of tolerance once administration of Xolair is terminated. We will examine the specific immunological mechanisms that mediate oral tolerance in children undergoing oral milk desensitization

The trial will be conducted in three parts: (1) pre-treatment with Xolair for 8 weeks, (2) oral desensitization to cow's milk from weeks 9-16 and continued treatment with Xolair for 8 weeks, and (3) double blind placebo controlled food challenge to milk.

Eligibility

Ages Eligible for Study:	4 Years to 18 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Moderate to severe pediatric cow's milk allergy-sensitive subjects between the ages of 4-18 years old.
Total IgE >30 kU/L
Sensitivity to cow's milk allergen will be documented by a positive skin prick test result (see Appendix E for details) and RAST test to cow's milk, with 25 kU/L as a lower limit of eligibility. Patients who do not meet the cow's milk RAST requirement may be eligible for this study if they have a history of a moderate to severe reaction, and if they have recently failed an oral food challenge with milk ordered by their physician.
All female subjects of child-bearing potential will be required to provide a urine sample for pregnancy testing that must be negative one week before being allowed to participate in the study.
Subjects must be planning to remain in the study area during the trial.
Subjects and/or their parents must be trained on the proper use of the Epi-Pen to be allowed to enroll in the study.

Exclusion Criteria:

No absolute contraindications to allergen skin testing and/or oral ingestion of milk are known. However, the risk of serious systemic anaphylactic reactions to milk suggests a number of preexisting conditions that should be considered relative contraindications. Among those conditions are acute infections, autoimmune disease, severe cardiac disease, and treatment with beta-adrenergic antagonistic drugs (beta-blockers).
Subjects having a history of severe anaphylaxis to milk requiring intubation or admission to an ICU, frequent allergic or non-allergic urticaria, or history consistent with poorly controlled persistent asthma.
Total IgE > 2000 IU/mL.
Subjects with unstable angina, significant arrhythmia, uncontrolled hypertension, chronic sinusitis, or other chronic or immunological diseases that in the mind of the investigator might interfere with the evaluation or administration of the test drug or pose additional risk to the subject e.g. gastrointestinal or gastroesophageal disease, chronic infections, scleroderma, hepatic and gallbladder disease, chronic non-allergic pulmonary disease.
Subject with an FEV1 or PEF less than 80% predicted (moderate persistent asthma) with or without controller medication (if able to perform the maneuver) at screening, the oral desensitization visit, or food challenge visit.
Subjects who have received an experimental drug in the last 30 days prior to admission into this study or who plan to use an experimental drug during the study.
Subjects who are current users of oral, intramuscular, or intravenous corticosteroids, tricyclic antidepressants, or are taking a beta-blocker (oral or topical).
Subjects routinely using medication that could induce adverse gastrointestinal reactions during the study.
Subjects refusing to sign the EpiPen Training Form (see Appendix F).
Pregnant or breast feeding females.
Subjects with a history of rice and soy allergy.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00968110

Locations

United States, California
Stanford Uneiversity Medical Center
Stanford, California, United States, 94305
United States, Massachusetts
Children's Hosptial Boston
Boston, Massachusetts, United States, 02115

Sponsors and Collaborators

Children's Hospital Boston

Stanford University

Investigators

Principal Investigator:

Dale Umetsu, MD

Children's Hospital Boston

More Information

No publications provided

Responsible Party:	Dale Umetsu, MD, PhD, Children's Hospital Boston
ClinicalTrials.gov Identifier:	NCT00968110 History of Changes
Other Study ID Numbers:	Milk-01
Study First Received:	August 27, 2009
Last Updated:	February 18, 2011
Health Authority:	United States: Food and Drug Administration

Keywords provided by Children's Hospital Boston:

Milk Allergy

Additional relevant MeSH terms:

Hypersensitivity
Milk Hypersensitivity
Immune System Diseases
Food Hypersensitivity
Hypersensitivity, Immediate
Omalizumab

Anti-Allergic Agents
Therapeutic Uses
Pharmacologic Actions
Anti-Asthmatic Agents
Respiratory System Agents

ClinicalTrials.gov processed this record on February 09, 2012